Company profile CNSP
After 39 days of this quarter the interest is at 84.0. Based on that we can calculate that during remaining 52 days it will total up to 196.0. CNS Pharmaceuticals expected interest is significantly higher compared to previous quarter (+833.3%) and same quarter last year (+345.5%).
| Year | Q1 | Q2 | Q3 | Q4 |
|---|---|---|---|---|
| 2019 | 13 | 0 -100.0% QoQ | 99 inf% QoQ | 125 26.3% QoQ |
| 2020 | 123 846.2% YoY -1.6% QoQ | 133 inf% YoY 8.1% QoQ | 63 -36.4% YoY -52.6% QoQ | 107 -14.4% YoY 69.8% QoQ |
| 2021 | 299 143.1% YoY 179.4% QoQ | 113 -15.0% YoY -62.2% QoQ | 35 -44.4% YoY -69.0% QoQ | 39 -63.6% YoY 11.4% QoQ |
| 2022 | 56 -81.3% YoY 43.6% QoQ | 42 -62.8% YoY -25.0% QoQ | 117 234.3% YoY 178.6% QoQ | 80 105.1% YoY -31.6% QoQ |
| 2023 | 44 -21.4% YoY -45.0% QoQ | 111 164.3% YoY 152.3% QoQ | 42 -64.1% YoY -62.2% QoQ | 21 -73.8% YoY -50.0% QoQ |
| 2024 | 84 90.9% YoY 300.0% QoQ | - | - | - |
The average 5 years interest of CNS Pharmaceuticals was 6.69 per week. The last year interest of CNS Pharmaceuticals compared to the last 5 years has changed by -23.77%. This is something to be checked. The last year interest is comparable to 5 years ago. It has changed only by -1.35%.
There is not enough data for Berubicin clinical trials to provide analysis
There is not enough data for Berubicin clinical trials to provide correlation calculation
There is not enough data for Berubicin clinical trials to provide analysis
After 39 days of this quarter the interest is at 226.0. Based on that we can calculate that during remaining 52 days it will total up to 527.0. That appears to be equal to previous quarter and same quarter last year.
| Year | Q1 | Q2 | Q3 | Q4 |
|---|---|---|---|---|
| 2019 | 542 | 816 50.6% QoQ | 628 -23.0% QoQ | 692 10.2% QoQ |
| 2020 | 573 5.7% YoY -17.2% QoQ | 488 -40.2% YoY -14.8% QoQ | 619 -1.4% YoY 26.8% QoQ | 577 -16.6% YoY -6.8% QoQ |
| 2021 | 555 -3.1% YoY -3.8% QoQ | 526 7.8% YoY -5.2% QoQ | 551 -11.0% YoY 4.8% QoQ | 421 -27.0% YoY -23.6% QoQ |
| 2022 | 650 17.1% YoY 54.4% QoQ | 614 16.7% YoY -5.5% QoQ | 627 13.8% YoY 2.1% QoQ | 623 48.0% YoY -0.6% QoQ |
| 2023 | 711 9.4% YoY 14.1% QoQ | 687 11.9% YoY -3.4% QoQ | 646 3.0% YoY -6.0% QoQ | 787 26.3% YoY 21.8% QoQ |
| 2024 | 226 -68.2% YoY -71.3% QoQ | - | - | - |
The average 5 years interest of Brain tumor treatment was 48.12 per week. The last year interest of Brain tumor treatment compared to the last 5 years has changed by 9.98%. The interest for Brain tumor treatment is seasonal. The last year interest is comparable to 5 years ago. It has changed only by -5.6%.
After 39 days of this quarter the interest is at 117.0. Based on that we can calculate that during remaining 52 days it will total up to 273.0. CNS Pharmaceuticals stock expected interest is significantly higher compared to previous quarter (+1336.8%) and same quarter last year (+1265.0%).
| Year | Q1 | Q2 | Q3 | Q4 |
|---|---|---|---|---|
| 2019 | 0 | 28 inf% QoQ | 20 -28.6% QoQ | 32 60.0% QoQ |
| 2020 | 4 inf% YoY -87.5% QoQ | 26 -7.1% YoY 550.0% QoQ | 26 30.0% YoY 0.0% QoQ | 42 31.2% YoY 61.5% QoQ |
| 2021 | 114 2750.0% YoY 171.4% QoQ | 35 34.6% YoY -69.3% QoQ | 40 53.8% YoY 14.3% QoQ | 10 -76.2% YoY -75.0% QoQ |
| 2022 | 45 -60.5% YoY 350.0% QoQ | 8 -77.1% YoY -82.2% QoQ | 18 -55.0% YoY 125.0% QoQ | 5 -50.0% YoY -72.2% QoQ |
| 2023 | 20 -55.6% YoY 300.0% QoQ | 27 237.5% YoY 35.0% QoQ | 5 -72.2% YoY -81.5% QoQ | 19 280.0% YoY 280.0% QoQ |
| 2024 | 117 485.0% YoY 515.8% QoQ | - | - | - |
The average 5 years interest of CNS Pharmaceuticals stock was 2.46 per week. The last year interest of CNS Pharmaceuticals stock compared to the last 5 years has changed by 41.46%. This is something to be checked. The last year interest is quite higher compared to 5 years ago. It has increased by 114.81%.
After 39 days of this quarter the interest is at 100.0. Based on that we can calculate that during remaining 52 days it will total up to 233.0. CNS Pharmaceuticals news expected interest is significantly higher compared to previous quarter (+1270.6%) and same quarter last year (+651.6%).
| Year | Q1 | Q2 | Q3 | Q4 |
|---|---|---|---|---|
| 2019 | 0 | 23 inf% QoQ | 17 -26.1% QoQ | 71 317.6% QoQ |
| 2020 | 11 inf% YoY -84.5% QoQ | 23 0.0% YoY 109.1% QoQ | 47 176.5% YoY 104.3% QoQ | 12 -83.1% YoY -74.5% QoQ |
| 2021 | 62 463.6% YoY 416.7% QoQ | 37 60.9% YoY -40.3% QoQ | 19 -59.6% YoY -48.6% QoQ | 38 216.7% YoY 100.0% QoQ |
| 2022 | 22 -64.5% YoY -42.1% QoQ | 32 -13.5% YoY 45.5% QoQ | 0 -100.0% YoY -100.0% QoQ | 9 -76.3% YoY inf% QoQ |
| 2023 | 31 40.9% YoY 244.4% QoQ | 41 28.1% YoY 32.3% QoQ | 35 inf% YoY -14.6% QoQ | 17 88.9% YoY -51.4% QoQ |
| 2024 | 100 222.6% YoY 488.2% QoQ | - | - | - |
The average 5 years interest of CNS Pharmaceuticals news was 2.48 per week. The last year interest of CNS Pharmaceuticals news compared to the last 5 years has changed by 49.6%. This is something to be checked. The last year interest is quite higher compared to 5 years ago. It has increased by 74.18%.
There is not enough data for CNS Pharmaceuticals Houston to provide analysis
There is not enough data for CNS Pharmaceuticals Houston to provide correlation calculation
There is not enough data for CNS Pharmaceuticals Houston to provide analysis
There is not enough data for CNS Pharmaceuticals jobs to provide analysis
There is not enough data for CNS Pharmaceuticals jobs to provide correlation calculation
There is not enough data for CNS Pharmaceuticals jobs to provide analysis
There is not enough data for CNS Pharmaceuticals competitors to provide analysis
There is not enough data for CNS Pharmaceuticals competitors to provide correlation calculation
There is not enough data for CNS Pharmaceuticals competitors to provide analysis
There is not enough data for CNS Pharmaceuticals partnerships to provide analysis
There is not enough data for CNS Pharmaceuticals partnerships to provide correlation calculation
There is not enough data for CNS Pharmaceuticals partnerships to provide analysis
There is not enough data for CNS Pharmaceuticals drug development to provide analysis
There is not enough data for CNS Pharmaceuticals drug development to provide correlation calculation
There is not enough data for CNS Pharmaceuticals drug development to provide analysis